4th Nov 2009 10:00
|
For immediate release |
4 November 2009 |
("Abcam" or "the Company")
Director and PDMR Dealings
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, announces the following transactions undertaken by employees of the Company:
On 3 November 2009, Jim Warwick, as Executive Director of the Company, exercised share options over 4,218 ordinary shares of 1 pence each in the Company at an exercise price of 224p per share. Following this transaction, Mr Warwick's total beneficial interest in the Company is 857,738 ordinary shares representing approximately 2.4 per cent. of the current issued share capital of the Company.
Also on 3 November 2009, Jane Cooke, a PDMR of the Company, exercised share options over 3,375 ordinary shares of 1 pence each in the Company at an exercise price of 224p per share. Following this transaction, Mrs Cooke's total beneficial interest in the Company is 3,724 ordinary shares representing approximately 0.01 per cent. of the current issued share capital of the Company.
For further information please contact:
|
Abcam |
+ 44 (0) 1223 696000 |
|
Jonathan Milner, Chief Executive Officer |
|
|
Jeffrey Iliffe, Chief Financial Officer |
|
|
Numis Securities |
+ 44 (0) 20 7260 1000 |
|
Michael Meade / Nick Westlake - Nominated Adviser |
|
|
James Black - Corporate Broking |
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
|
Mark Court / Mary-Jane Johnson / Stasa Filiplic |
|
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA, Tokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 56,000 products, most of which are antibodies, from over 250 suppliers and employs 243 staff in its four operating companies.
Related Shares:
ABC.L